Summary Three out of four patients with primary (light chain) amyloid nephrotic syndrome treated with vincristine, doxorubicin and dexamethasone (VAD) induction obtained a partial response and are alive in continuing remission at 4.1, 6.5 and 9.3 years. These preliminary results are of considerable interest and suggest that prospective evaluation of this regimen is warranted in patients with this condition.
Patients with nephrotic syndrome, normal serum creatinine and no cardiac involvement may represent a better prognostic group with higher response rates (30-39%) and longer median survival (Kyle and Greipp, 1983; Kyle et al, 1985; Marione et al, 1994; Merlini et al, 1995; Skinner et al, 1996) . Patients whose disease responds to treatment have a 5-year survival of 50-78%, although the median survival of the whole population is 12-28 months (Kyle and Greipp, 1983; Kyle et al, 1985 Kyle et al, , 1997 Fielder and Durie, 1986; Skinner et al, 1996) .
Combination chemotherapy for AL amyloidosis has been used less widely, mainly because of poor performance status and perceived unsuitability of patients for such treatments, and it is often used after melphalan resistance has occurred (Case et al, 1977; Fielder and Durie, 1986; Levy et al, 1988) . As vincristine, doxorubicin and dexamethasone (VAD) chemotherapy is considerably more effective when used at presentation of multiple myeloma than as salvage (Anderson et al, 1995) , we were prompted to evaluate this regimen for first-line therapy in primary light chain amyloid (AL).
METHODS
We retrospectively analysed the outcome of patients with a biopsyproven diagnosis of AL (11 patients) and nephrotic syndrome (NS) referred to the Christie Hospital between 1985 and 1996, and present the results as a preliminary descriptive study. Nephrotic syndrome was defined as 24-h urinary total protein (UTP) > 3 g, hypoalbuminaemia (< 30 g 1-') and oedema. Ten patients were diagnosed by renal biopsy following presentation with NS and were previously untreated. One patient was diagnosed by subcutaneous fat aspiration following the development of NS 3 years after initial presentation with myeloma and vertebral AL that had been treated with melphalan and prednisolone (MP). Amyloid was diagnosed with Congo red stain and classified using immunohistochemistry (Linke et al, 1986) . Monoclonal A partial response (PR) was defined as a reduction in UTP to < 3 g without progression of renal failure, the return of serum albumin to the normal range (> 30 g 1-'), together with a complete resolution of serum/urine monoclonal protein.
RESULTS
The two treatment groups and supportive care controls appear similar with respect to age, mean arterial blood pressure, VAD treatment of AL-induced nephrotic syndrome 775 The interval between diagnosis and treatment was 6-65 (median 6) and 40-497 (median 138) days for the VAD-and MPtreated group respectively. The VAD group had a lower performance status and was deemed to require immediate treatment. The response rates and survival characteristics are shown in Table  2 . Three out of four patients achieved PR with VAD and are alive and in remission 4.1, 6.5 and 9.3 years (median survival of group 64.5 months) from diagnosis, whereas those treated with supportive care survived for a median of 11.7 months with no spontaneous responses. Two of seven patients treated with MP alone achieved PR, of whom only one is alive and in continuing PR at 3.6 years; the second died of refractory anaemia with excess of blasts in transformation (RAEBt) after 7.1 years. The median survival in this group was 17.7 months. One patient in each treatment group died of gastrointestinal haemorrhage related to autopsy-proven gastric amyloid. When VAD was commenced after failure of MP in two patients no response was achieved, although one patient remains alive at 13 months having received three cycles of VAD, the other died of gastrointestinal haemorrhage after three cycles of VAD.
In this group of patients with amyloid treated with VAD, the toxicity was similar to that seen when patients with myeloma are treated with VAD.
Treatment of patients with poor prognostic features can be successful: a 49-year-old man with a performance status of 40% (Karnofsky et al, 1948) (Hawkins et al, 1988) . The patient was treated with six cycles of VAD, followed by 6-weekly oral melphalan and prednisolone (MP) and subsequently ox2b-interferon. Improvement was rapid with a 50% reduction in serum monoclonal protein concentration and urinary total protein after six cycles of VAD and only three of melphalan and prednisolone (322 days). Partial response was achieved after 3.9 years. The patient remains in continuing PR with a good performance status and a daily UTP < 3 g 4 years later and a recent SAP scan showed only minor abnormalities of kidneys, liver and spleen with continuing improvement since commencing interferon. The other two VAD responders had a reduction in UTP from 7.1 and 3.4 to < 0.05 g. The latter also had hepatic involvement, which resolved completely (disappearance of hepatomegaly and normalization of deranged liver function tests).
DISCUSSION
These preliminary data support the further investigation of VAD as the initial treatment regimen for AL. Treatment was not allocated by randomization and there are clearly differences between the two groups. For example, more patients fulfilled the diagnostic criteria for myeloma (Salmon and Cassady, 1993) in the VADtreated group. The presence or absence of myeloma is not, however, a prognostic factor for survival in the first year after diagnosis (Kyle and Gertz, 1995) . Both sets of patients had similar median age, performance status, proteinuria, hypoalbuminaemia British Journal of Cancer (1998) 78(6), [774] [775] [776] . Cancer Research Campaign 1998 and renal impairment. Cardiac amyloid is a poor prognostic factor (Gertz et al, 1991; Kyle and Gertz, 1995; Skinner et al, 1996) and there was one patient in each treatment group. The PR rate in three of four VAD-treated patients is interesting and includes the most severely affected patient. The response rate in those receiving MP (two of seven) was similar to the response rates in published series from randomized trials (Kyle and Greipp, 1983; Kyle et al, 1985 Kyle et al, , 1997 Marione et al, 1994; Merlini et al, 1995) . The fact that VAD was followed by MP makes interpretation difficult. The time to response was shorter in those treated with VAD than MP alone (median 357 and 659 days to PR respectively) and all three exhibited evidence of response before commencement of MP. The survival of VAD-treated patients is better than that of melphalantreated patients and control subjects treated with supportive care. We believe that this report will be of interest to clinicians who treat AL. We have shown that VAD can be used in patients of poor performance and it may have an advantage in patients with moderate to severe renal impairment, as the drugs are not renally excreted. Aggressive myeloablative therapy with high-dose melphalan has recently been shown to be possible in some patients (Comenzo et al, 1996) . Patients with NS caused by AL should be considered for chemotherapy. Prospective randomized trials are required to assess the benefits of newer regimens, such as VAD, over conventional treatment with melphalan and prednisolone. ABBREVIATIONS AL, primary (light-chain) amyloid; MP, melphalan and prednisolone; NS, nephrotic syndrome; PR, partial response; SAP, serum amyloid P component; UTP; 24-h urinary total protein; VAD, vincristine, doxorubicin and dexamethasone combination chemotherapy.
